France is trialing a “direct access” system to cut the time it takes to get innovative products to patients after marketing approval. It will mean that patients can access eligible products before a formal agreement on pricing has been agreed and that companies will be able to freely set the prices of their products, which will remain valid for one year.
The direct access scheme will complement the existing early access system for unapproved medicines, which was itself refined by the 2022 social security financing law, said the health ministry. (Also...